Free Access
Issue
Med Sci (Paris)
Volume 30, Number 8-9, Août–Septembre 2014
Page(s) 765 - 771
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143008014
Published online 01 September 2014
  1. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004 ; 5 : 1109–1115. [CrossRef] [PubMed] [Google Scholar]
  2. Rajsbaum R, Garcia-Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 2013 ; 426 : 1265–1284. [CrossRef] [PubMed] [Google Scholar]
  3. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005 ; 3 : 799–808. [CrossRef] [PubMed] [Google Scholar]
  4. McNab FW, Rajsbaum R, Stoye JP, O’Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011 ; 23 : 46–56. [CrossRef] [PubMed] [Google Scholar]
  5. De Thé H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991 ; 66 : 675–684. [CrossRef] [PubMed] [Google Scholar]
  6. Nisole S, Maroui MA, Mascle XH, et al. Differential roles of PML isoforms. Front Oncol 2013 ; 3 : 125. [CrossRef] [PubMed] [Google Scholar]
  7. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001 ; 20 : 7223–7233. [CrossRef] [PubMed] [Google Scholar]
  8. Ishov AM, Sotnikov AG, Negorev D, et al. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 1999 ; 147 : 221–234. [CrossRef] [PubMed] [Google Scholar]
  9. Bernardi R, Papa A, Pandolfi PP. Regulation of apoptosis by PML and the PML-NBs. Oncogene 2008 ; 27 : 6299–6312. [CrossRef] [PubMed] [Google Scholar]
  10. Krieghoff-Henning E, Hofmann TG. Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta 2008 ; 1783 : 2185–2194. [CrossRef] [PubMed] [Google Scholar]
  11. Jin G, Wang YJ, Lin HK. Emerging cellular functions of cytoplasmic PML. Front Oncol 2013 ; 3 : 147. [PubMed] [Google Scholar]
  12. Martin N, Dejean A, Bischof O. TBX2, un nouvel acteur dans la sénescence cellulaire induite par PML. Med Sci (Paris) 2012 ; 28 : 248–250. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Chelbi-Alix MK, Quignon F, Pelicano L, et al. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 1998 ; 72 : 1043–1051. [PubMed] [Google Scholar]
  14. Regad T, Saib A, Lallemand-Breitenbach V, et al. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 2001 ; 20 : 3495–3505. [CrossRef] [PubMed] [Google Scholar]
  15. Pampin M, Simonin Y, Blondel B, et al. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 2006 ; 80 : 8582–8592. [CrossRef] [PubMed] [Google Scholar]
  16. Blondel D, Kheddache S, Lahaye X, et al. Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 2010 ; 84 : 10719–10726. [CrossRef] [PubMed] [Google Scholar]
  17. Maroui MA, Pampin M, Chelbi-Alix MK. Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J Virol 2011 ; 85 : 13164–13173. [CrossRef] [PubMed] [Google Scholar]
  18. El Asmi F, Maroui MA, Dutrieux J, et al. Implication of PMLIV in both intrinsic and innate immunity. PLoS Pathog 2014 ; 10 : e1003975. [CrossRef] [PubMed] [Google Scholar]
  19. Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001 ; 20 : 7274–7286. [CrossRef] [PubMed] [Google Scholar]
  20. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007 ; 89 : 819–830. [CrossRef] [PubMed] [Google Scholar]
  21. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res 2011 ; 31 : 145–158. [CrossRef] [PubMed] [Google Scholar]
  22. Chelbi-Alix MK, Wietzerbin J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 2007 ; 89 : 713–718. [CrossRef] [PubMed] [Google Scholar]
  23. Chelbi-Alix MK, Pelicano L, Quignon F, et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995 ; 9 : 2027–2033. [PubMed] [Google Scholar]
  24. Stadler M, Chelbi-Alix MK, Koken MH, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995 ; 11 : 2565–2573. [PubMed] [Google Scholar]
  25. El Bougrini J, Dianoux L, Chelbi-Alix MK. PML positively regulates interferon gamma signaling. Biochimie 2011 ; 93 : 389–398. [CrossRef] [PubMed] [Google Scholar]
  26. Bonilla WV, Pinschewer DD, Klenerman P, et al. Effects of promyelocytic leukemia protein on virus-host balance. J Virol 2002 ; 76 : 3810–3818. [CrossRef] [PubMed] [Google Scholar]
  27. McNally BA, Trgovcich J, Maul GG A, et al. role for cytoplasmic PML in cellular resistance to viral infection. PloS one 2008 ; 3 : e2277. [CrossRef] [PubMed] [Google Scholar]
  28. Reichelt M, Wang L, Sommer M, et al. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog 2011 ; 7 : e1001266. [CrossRef] [PubMed] [Google Scholar]
  29. Cuchet D, Sykes A, Nicolas A, et al. PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 2011 ; 124 : 280–291. [CrossRef] [PubMed] [Google Scholar]
  30. Mitchell AM, Hirsch ML, Li C, Samulski RJ. Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication. J Virol 2014 ; 88 : 925–936. [CrossRef] [PubMed] [Google Scholar]
  31. Aminev AG, Amineva SP, Palmenberg AC. Encephalomyocarditis virus (EMCV) proteins 2A and 3BCD localize to nuclei and inhibit cellular mRNA transcription but not rRNA transcription. Virus Res 2003 ; 95 : 59–73. [CrossRef] [PubMed] [Google Scholar]
  32. El Mchichi B, Regad T, Maroui MA, et al. SUMOylation promotes PML degradation during encephalomyocarditis virus infection. J Virol 2010 ; 84 : 11634–11645. [CrossRef] [PubMed] [Google Scholar]
  33. Kyratsous CA, Silverstein SJ. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol 2009 ; 83 : 4262–4274. [CrossRef] [PubMed] [Google Scholar]
  34. Yaffe MB, Schutkowski M, Shen M, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997 ; 278 : 1957–1960. [CrossRef] [PubMed] [Google Scholar]
  35. Liou YC, Zhou XZ, Lu KP. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011 ; 36 : 501–514. [CrossRef] [PubMed] [Google Scholar]
  36. Saitoh T, Tun-Kyi A, Ryo A, et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 2006 ; 7 : 598–605. [CrossRef] [PubMed] [Google Scholar]
  37. Yang K, Shi HX, Liu XY, et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 2009 ; 182 : 3782–3792. [CrossRef] [PubMed] [Google Scholar]
  38. Imler JL, Ferrandon D. Le printemps de l’immunité innée couronné à Stockholm. Med Sci (Paris) 2001 ; 27 : 1019–1024. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Jemilloux Y, Henry T. Les inflammasomes. Plates-formes de l’immunité innée. Med Sci (Paris) 2013 ; 29 : 975–984. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  40. Marsolier J, Weitzman JB. Pin1 : une peptidyl prolyl cis-trans isomérase multifonctionnelle et une cible anticancéreuse prometteuse. Med Sci (Paris) 2014 ; 30 : 772–778. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.